DC-DORSEY-&-WHITNEY-LLP
2.11.2020 18:26:12 CET | Business Wire | Press release
International law firm Dorsey & Whitney LLP announced today that former senior CFIUS official Justin Huff has joined the Firm as a Partner in its Washington D.C. office.
Before entering private practice, Mr. Huff served as a Deputy Director in the United States Department of the Treasury office responsible for chairing the Committee on Foreign Investment in the United States (CFIUS), an interagency committee that reviews cross-border mergers, acquisitions and certain investment transactions for potential national security concerns. Mr. Huff led the review of hundreds of CFIUS filings and conducted in-depth national security analyses on transactions across a wide range of industries, including biotech, agriculture, technology, telecommunication, real estate, energy, and others. Mr. Huff also engaged in extensive inter-agency communications and consensus building with the eight other agencies on the CFIUS committee.
Before his Treasury position, Mr. Huff served as a senior intelligence analyst for the Office of Homeland Security and Emergency Coordination at the U.S. Department of Agriculture, where he managed departmental requirements and briefed White House officials and other federal agencies. He also was a senior intelligence advisor at the Office of the Director of National Intelligence, where he worked across federal departments and agencies to rally interagency support for initiatives that enhanced intelligence and information sharing between federal departments and the intelligence community.
After serving in the federal government as a national security official for over a decade, Mr. Huff entered the private law practice at another international law firm. Mr. Huff guided domestic and international clients on CFIUS regulations and their impact on hundreds of high-profile cross-border corporate transactions. Clients praise Mr. Huff for his deep knowledge of the CFIUS regulations and process, and for his ability to find practical and business-sensitive solutions, whether for a pending transaction or in connection with a post-closing CFIUS investigation or review.
Mr. Huff joins an experienced team of Dorsey attorneys who have filed and handled CFIUS notices and investigations on behalf of domestic and international clients in cross-border M&A and investment transactions since 1988. The lawyers at Dorsey have appeared for various clients before CFIUS and, through that extensive experience, have developed excellent, close, and mutually respectful relationships with CFIUS management and staff, including, where appropriate, the ability to meet directly with those officials in Washington, DC.
“With his experience as a senior CFIUS officer, Justin is knowledgeable not only about CFIUS regulations but also about the internal CFIUS processes and practice,” said Dorsey managing partner Bill Stoeri. “In light of the significant changes in CFIUS regulations, including the adoption of the Foreign Investment Risk Review Modernization Act of 2018 (FIRRMA), the expansion of CFIUS jurisdiction, the mandatory filing requirements and expansion of CFIUS’s operations and enforcement, Justin’s expertise and experience will help Dorsey clients with the growing regulatory demands placed on cross-border transactions.”
About Dorsey & Whitney LLP
Clients have relied on Dorsey since 1912 as a valued business partner. With locations across the United States and in Canada, Europe and the Asia-Pacific region, Dorsey provides an integrated, proactive approach to its clients' legal and business needs. Dorsey represents a number of the world's most successful companies from a wide range of industries, including leaders in banking & financial institutions, development & infrastructure, energy & natural resources, food, beverage & agribusiness, healthcare and technology, as well as major non-profit and government entities. www.dorsey.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20201102005791/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AI Meets Traditional Culture: Huangshan Captures Widespread Attention at ITB Berlin7.3.2026 10:22:00 CET | Press release
Huangshan, one of China’s most iconic scenic destinations, drew significant attention at this year’s ITB by presenting a compelling fusion of traditional Chinese culture and cutting-edge artificial intelligence under the slogan “The world of Huangshan is for the world.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260307909978/en/ International visitor admires Huangshan cultural and creative exhibits at the Huangshan stand during ITB Berlin. Located in eastern China’s Anhui Province, Huangshan is famed for its “Five Natural Wonders” — fantastic pines, grotesque rocks, sea of clouds, hot spring and winter snow. The mountain is widely regarded as one of China’s greatest mountain landscapes. It is also a rare natural heritage site that simultaneously holds multiple international designations, including UNESCO World Cultural and Natural Heritage status, a UNESCO Global Geopark and a World Biosphere Reserve. At ITB, the Huangsh
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press release
- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meur
Dfns Launches Payouts6.3.2026 21:27:00 CET | Press release
Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i
Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press release
Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 18:30:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
